TCTR20210326006
Active, not recruiting
Phase 2
A double-blind randomized placebo-controlled study of Desvenlafaxine for managing vasomotor symptoms in breast cancer survivors
ConditionsVasomotor symptoms
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Vasomotor symptoms
- Sponsor
- Khon Kaen University
- Enrollment
- 60
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women, who were diagnosed breast cancer, have moderate to severe vasomotor symptoms
Exclusion Criteria
- •1\. Allergy to SSRI and SNRI
- •2\. Hormonal treatment within 4 weeks prior
- •3\. History of epilepsy
- •4\. History of myocardial infarction within 6 months prior
- •5\. History of depression, bipolar disease or psychological conditions
- •6\. History of glaucoma or increased intraocular pressure
- •7\. Malabsorption
- •8\. Hypertension
- •9\. Impaired liver or renal disease
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Efficacy of Ashwagandha extract on generalized anxiety disorderCTRI/2022/04/042133Arjuna Natural Private Limited60
Completed
Not Applicable
A randomized double-blind placebo-controlled study for effects of aged garlic extract on fatigueJPRN-UMIN000017095Momoya Co., Ltd.40
Active, not recruiting
Phase 1
ALASCCA-A randomized double-blind placebo-controlled study with ASAtreatment in colorectal cancer patients with mutations in the PI3Ksignaling pathway.Colon or rectal cancer tumor stage II-III, tumor with somatic alterationsin PIK3CA, PIK3R1 or PTEN.MedDRA version: 21.0Level: LLTClassification code 10010029Term: Colorectal cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-004240-19-DKKarolinska University Hospital, Department of Molecular medicine and Surgery Karolinska Institutet, Gastrocentrum600
Not yet recruiting
Phase 3
ALASCCA-A randomized double-blind placebo-controlled study with ASA treatment in colorectal cancer patients with mutations in the PI3K signaling pathway2024-513778-23-00Karolinska Institutet700
Completed
Phase 3
To determine whether Flexsure is safe, tolerable and effective in relieving symptoms of moderate osteoarthritis of the knee.Health Condition 1: null- OsteoarthritisCTRI/2011/07/001911Vital gNetics60